Pharma Focus Europe

Biocon Biologics Acquires Viatris' Global Biosimilars Business

Wednesday, November 30, 2022

Biocon Biologics Ltd. (BBL) has successfully completed its multi-billion dollar acquisition of the global biosimilars business of its partner Viatris Inc.

This acquisition builds on Biocon’s long-standing, strategic partnership with Viatris and is a historic milestone in Biocon Biologics’ value creation journey.

This acquisition strengthens Biocon Biologics’ commitment to expand affordable access to lifesaving biosimilars worldwide, thus addressing global health inequities.

This acquisition provides Biocon Biologics direct commercial presence in advanced markets as well as several emerging markets.

The integration of Viatris’ direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets complements Biocon Biologics’ existing capabilities in R&D and global scale manufacturing of biosimilars.

Biocon Biologics will recognize the combined revenue & associated profits from the acquired collaboration biosimilars with immediate effect, a step-up from the existing profit share arrangement.

This acquisition will bring Biocon Biologics closer to patients, customers, and payors in the advanced markets and several emerging markets.

An ‘end to end’ integrated biosimilars organization, Biocon Biologics aspires to expand access and enhance the quality of experience of customers, partners and patients.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva